LOQPF yields 59.70% · PFE yields 6.13%● Live data
📍 LOQPF pulled ahead of the other in Year 1
Combined, LOQPF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LOQPF + PFE for your $10,000?
accesso Technology Group plc, together with its subsidiaries, develops technology solutions for the attractions and leisure industry in the United Kingdom, other European countries, Australia, the South Pacific, the United States, Canada, and Central and South America. The company operates through Ticketing and Distribution, and Guest Experience segments. It offers ticketing solutions for fairs and festivals, performing arts, ski, theme parks, tours and attractions, water parks, and zoos and aquariums, as well as cultural facilities. The company also offers various solutions, such as accesso LoQueue, a virtual queuing solution; the experience engine, an experience management platform; and accesso Passport ticketing suite, which provides season pass, group tickets, meal vouchers, and other services. In addition, it provides accesso Siriusware, which offers software solutions comprising ticketing and admissions, memberships, reservations, resource scheduling, retail, food service, gift cards, kiosks, and ecommerce; and accesso ShoWare ticketing solutions for box office, kiosk, online, mobile, call center, and social media sales. The company was formerly known as Lo-Q plc and changed its name to accesso Technology Group plc in November 2013. accesso Technology Group plc was incorporated in 2000 and is based in Twyford, the United Kingdom.
Full LOQPF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.